467 related articles for article (PubMed ID: 29518208)
1. 1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium.
Carter GP; Harjani JR; Li L; Pitcher NP; Nong Y; Riley TV; Williamson DA; Stinear TP; Baell JB; Howden BP
J Antimicrob Chemother; 2018 Jun; 73(6):1562-1569. PubMed ID: 29518208
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
Barber KE; Smith JR; Raut A; Rybak MJ
J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
[TBL] [Abstract][Full Text] [Related]
3. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.
Neudorfer K; Schmidt-Malan SM; Patel R
Diagn Microbiol Infect Dis; 2018 Jan; 90(1):58-63. PubMed ID: 29195766
[TBL] [Abstract][Full Text] [Related]
4. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
[TBL] [Abstract][Full Text] [Related]
7. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.
Smith JR; Barber KE; Raut A; Aboutaleb M; Sakoulas G; Rybak MJ
J Antimicrob Chemother; 2015; 70(6):1738-43. PubMed ID: 25645208
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I
Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
Belley A; Arhin FF; Moeck G
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
11. Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy.
Lellek H; Franke GC; Ruckert C; Wolters M; Wolschke C; Christner M; Büttner H; Alawi M; Kröger N; Rohde H
Int J Med Microbiol; 2015 Dec; 305(8):902-9. PubMed ID: 26454536
[TBL] [Abstract][Full Text] [Related]
12. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 May; 59(5):2842-8. PubMed ID: 25753639
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010).
Sader HS; Moet GJ; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):412-6. PubMed ID: 21546202
[TBL] [Abstract][Full Text] [Related]
14. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an
Belley A; Lalonde-Séguin D; Arhin FF; Moeck G
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784674
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
16. Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection.
Alder J; Li T; Yu D; Morton L; Silverman J; Zhang XX; Critchley I; Thorne G
Antimicrob Agents Chemother; 2003 Nov; 47(11):3561-6. PubMed ID: 14576118
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin-resistant Enterococcus faecium in Algeria: phenotypic and genotypic characterization of clinical isolates.
Benamrouche N; Guettou B; Henniche FZ; Assaous F; Laouar H; Ziane H; Djennane F; Tiouit D; Bentchouala C; Yamouni F; Rahal K; Tali Maamar H
J Infect Dev Ctries; 2021 Jan; 15(1):95-101. PubMed ID: 33571151
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E
J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495
[TBL] [Abstract][Full Text] [Related]
19. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
20. Institution-wide and Within-Patient Evolution of Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium Bloodstream Infections.
Woods RJ; Patel TS; Nagel JL; Newton DW; Read AF
Infect Control Hosp Epidemiol; 2018 Feb; 39(2):226-228. PubMed ID: 29331166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]